{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:26:29Z","timestamp":1790141189646,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health Research Biomedical Research Centre based at Imperial College London","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leukemia (ALL) has been established and MRD measured at the end of induction is increasingly used to guide further therapy. Although MRD detectable immediately before allogeneic hematopoietic cell transplantation (HCT) is known to be associated with poor outcomes, it is unclear if or to what extent this differs with different types of conditioning.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective registry study, we explored whether measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia is associated with different outcomes in recipients of myeloablative total body irradiation (TBI)-based versus chemotherapy-based conditioning. We analyzed outcomes of 2780 patients (median age 38\u2009years, range 18\u201372) who underwent first HCT in complete remission between 2000 and 2017 using sibling or unrelated donors.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 1816 of patients, no disease was detectable, and in 964 patients, MRD was positive. Conditioning was TBI-based in 2122 (76%) transplants. In the whole cohort MRD positivity was a significant independent factor for lower overall survival (OS) and leukemia-free survival (LFS), and for higher relapse incidence (RI), with respective hazard ratios (HR, 95% confidence intervals) of 1.19 (1.02\u20131.39), 1.26 (1.1\u20131.44), and 1.51 (1.26\u20131.8). TBI was associated with a higher OS, LFS, and lower RI with HR of 0.75 (0.62\u20130.90), 0.70 (0.60\u20130.82), and 0.60 (0.49\u20130.74), respectively. No significant interaction was found between MRD status and conditioning. When investigating the impact of MRD separately in the TBI and chemotherapy-based conditioning cohorts by multivariate analysis, we found MRD positivity to be associated with lower OS and LFS and higher RI in the TBI group, and with higher RI in the chemotherapy group. TBI-based conditioning was associated with improved outcomes in both MRD-negative and MRD-positive patients.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this large study, we confirmed that patients who are MRD-negative prior to HCT achieve superior outcomes. This is particularly apparent if TBI conditioning is used. All patients with ALL irrespective of MRD status benefit from TBI-based conditioning in the myeloablative setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-019-0790-x","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T17:03:41Z","timestamp":1571850221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-5637","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"Pavl\u016f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Niittyvuopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Remenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich W.","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"790_CR1","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.","journal-title":"JAMA Oncol"},{"key":"790_CR2","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1182\/blood.V92.11.4072","volume":"92","author":"CJ Knechtli","year":"1998","unstructured":"Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92:4072\u20139.","journal-title":"Blood"},{"key":"790_CR3","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/sj.leu.2402552","volume":"16","author":"P Bader","year":"2002","unstructured":"Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia. 2002;16:1668\u201372.","journal-title":"Leukemia"},{"key":"790_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/pbc.20794","volume":"48","author":"L Sramkova","year":"2007","unstructured":"Sramkova L, Muzikova K, Fronkova E, et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;48:93\u2013100.","journal-title":"Pediatr Blood Cancer"},{"key":"790_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3324\/haematol.10965","volume":"92","author":"O Spinelli","year":"2007","unstructured":"Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92:612\u20138.","journal-title":"Haematologica"},{"key":"790_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.bbmt.2010.12.699","volume":"17","author":"K Doney","year":"2011","unstructured":"Doney K, Gooley TA, Deeg HJ, Flowers MED, Storb R, Appelbaum FR. Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. Biol Blood Marrow Transplant. 2011;17:1187\u201395.","journal-title":"Biol Blood Marrow Transplant"},{"key":"790_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","volume":"27","author":"P Bader","year":"2009","unstructured":"Bader P, Kreyenberg H, Henze GHR, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group. J Clin Oncol. 2009;27:377\u201384.","journal-title":"J Clin Oncol"},{"key":"790_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1186\/s12885-018-4670-5","volume":"18","author":"Z Shen","year":"2018","unstructured":"Shen Z, Gu X, Mao W, et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18:755.","journal-title":"BMC Cancer"},{"key":"790_CR9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"MH Gilleece","year":"2018","unstructured":"Gilleece MH, Labopin M, Yakoub-Agha I, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the acute leukemia working party E. Am J Hematol. 2018;93:1142\u201352.","journal-title":"Am J Hematol"},{"key":"790_CR10","unstructured":"European Society for Blood and Marrow Transplantation. \n                    www.ebmt.org\n                    \n                  . Accessed 10 Dec 2018."},{"key":"790_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"790_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP\u2013EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610\u20131.","journal-title":"Bone Marrow Transplant"},{"key":"790_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF00985760","volume":"1","author":"P Hougaard","year":"1995","unstructured":"Hougaard P. Frailty models for survival data. Lifetime Data Anal. 1995;1:255\u201373.","journal-title":"Lifetime Data Anal"},{"key":"790_CR14","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","volume":"18","author":"PK Andersen","year":"1999","unstructured":"Andersen PK, Klein JP, Zhang MJ. Testing for Centre effects in multi-Centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489\u2013500.","journal-title":"Stat Med"},{"key":"790_CR15","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2008","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2008. \n                    http:\/\/www.R-project.org"},{"key":"790_CR16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJM199703273361301","volume":"336","author":"RE Curtis","year":"1997","unstructured":"Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897\u2013904.","journal-title":"N Engl J Med"},{"key":"790_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.1958.tb06038.x","volume":"4","author":"LA Elson","year":"1958","unstructured":"Elson LA, Galton DA, Till M. The action of chlorambucil (CB. 1348) and busulphan (myleran) on the haemopoietic organs of the rat. Br J Haematol. 1958;4:355\u201374.","journal-title":"Br J Haematol"},{"key":"790_CR18","first-page":"341","volume":"20","author":"HJ Kolb","year":"1974","unstructured":"Kolb HJ, Storb R, Weiden PL, et al. Immunologic, toxicologic and marrow transplantation studies in dogs given dimethyl myleran. Biomedicine. 1974;20:341\u201351.","journal-title":"Biomedicine"},{"key":"790_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/sj.bmt.1704198","volume":"32","author":"N Bunin","year":"2003","unstructured":"Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2003;32:543\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"790_CR20","unstructured":"Peters C et al. ALL SCTped 2012 FORUM trial. Available at: \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01949129\n                    \n                   [Accessed 9 Sept. 2019]."},{"key":"790_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S, Labopin M, Soci\u00e9 G, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the acute leukemia working party of the European Society for blood and marrow transplantation. Haematologica. 2017;102:139\u201349.","journal-title":"Haematologica"},{"key":"790_CR22","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/cncr.30604","volume":"123","author":"J Pavl\u016f","year":"2017","unstructured":"Pavl\u016f J, Labopin M, Zoellner AK, et al. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: a report from the acute leukemia working party of the EBMT. Cancer. 2017;123:1965\u201370.","journal-title":"Cancer"},{"key":"790_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/bmt.2015.278","volume":"51","author":"X Cahu","year":"2016","unstructured":"Cahu X, Labopin M, Giebel S, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016;51:351\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"790_CR24","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134\u201340.","journal-title":"J Clin Oncol"},{"key":"790_CR25","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","volume":"1","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv. 2017;1:1167\u201380.","journal-title":"Blood Adv"},{"key":"790_CR26","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"790_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","volume":"4","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4:230\u20134.","journal-title":"JAMA Oncol"},{"key":"790_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Wang Y, Liu YR, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134.","journal-title":"J Hematol Oncol"},{"key":"790_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","volume":"24","author":"J Mariotti","year":"2018","unstructured":"Mariotti J, Devillier R, Bramanti S, et al. T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors. Biol Blood Marrow Transplant. 2018;24:627\u201332.","journal-title":"Biol Blood Marrow Transplant"},{"key":"790_CR30","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","volume":"84","author":"RA Clift","year":"1994","unstructured":"Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036\u201343.","journal-title":"Blood"},{"key":"790_CR31","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"A Nagler","year":"2013","unstructured":"Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (cy) versus total-body irradiation plus cy as conditioning regimen\u2014a report from the acute leukemia working Party of the European Group for blood and marrow transplantation. J Clin Oncol. 2013;31:3549\u201356.","journal-title":"J Clin Oncol"},{"key":"790_CR32","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","volume":"83","author":"O Ringden","year":"1994","unstructured":"Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic bone marrow transplantation group. Blood. 1994;83:2723\u201330.","journal-title":"Blood"},{"key":"790_CR33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"S Giebel","year":"2019","unstructured":"Giebel S, Marks DI, Boissel N, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 2019;54:798\u2013809.","journal-title":"Bone Marrow Transplant"},{"key":"790_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clml.2014.01.002","volume":"14","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Slack R, Jorgensen JL, et al. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014;14:319\u201326.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"790_CR35","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","volume":"125","author":"N Dhedin","year":"2015","unstructured":"Dhedin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125:2486\u201396.","journal-title":"Blood"},{"key":"790_CR36","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/cncr.28768","volume":"120","author":"S Giebel","year":"2014","unstructured":"Giebel S, Miszczyk L, Slosarek K, et al. Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the acute leukemia working party of the European Group for blood and marrow transplantation: TBI techniques in current clinical practice. Cancer. 2014;120:2760\u20135.","journal-title":"Cancer"},{"key":"790_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ccr3.604","volume":"4","author":"MW Khan","year":"2016","unstructured":"Khan MW, Gul Z. Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant. Clin Case Rep. 2016;4:743\u20136.","journal-title":"Clin Case Rep"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0790-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-019-0790-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0790-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T23:15:35Z","timestamp":1603322135000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0790-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1186\/s13045-019-0790-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"19 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific boards of the ALWP of EBMT approved this study. All patients gave written informed consent for the use of their data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}